NCT06772415 - A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

March 31, 2031

Conditions

Advanced Solid Tumor

Interventions

DRUG

GenSci122 tablet 50mg

Orally Once Daily

DRUG

GenSci122 tablet 250mg

Orally Once Daily

Trial Locations (9)

45000

NOT_YET_RECRUITING

The first affiliated hospital of Zhengzhou university, Zhengzhou

100000

RECRUITING

Beijing Cancer Hospital, Beijing

100021

NOT_YET_RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

200032

NOT_YET_RECRUITING

ZhongShan Hospital Fudan University, Shanghai

210029

NOT_YET_RECRUITING

Jiang Su Province Hospital, Nanjing

250117

NOT_YET_RECRUITING

Cancer Hospital of Shandong First Medical University, Jinan

300060

NOT_YET_RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

410013

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY